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Abstract
Tuberculosis (TB) is still one of the major health problems in the community. Micronutrients, including iron, are 
crucial in the body's defense mechanism. Iron modulates the activation of IFN-γ, which in turn will activate the 
macrophages. This study explores the effect of iron supplementation given with anti-tuberculosis drug therapy on 
the IFN-γ level in tuberculosis spondylitis patients. This was a single-blind randomized control trial study at Dr. 
Hasan Sadikin General Hospital Bandung, from December 2018 to March 2019, using the consecutive sampling 
approach. Thirty-four respondents with category 1 TB spondylitis and an sTfR level of >21.7 pg /µL were recruited 
and randomized into control and experimental groups. The control group (n=17) was treated with 2 RHZE for 2 
months while the experimental group (n=17) received 2 RHZE and iron tablet for 2 months. An increase in the 
IFN-γ level of the experimental group was observed from an average of 21.7 pg/mL before therapy to an average 
of 72.39 pg/mL after therapy. Meanwhile, the IFN-γ level in the control group increases from an average of 22.5 
pg/mL to an average of 35.35 pg/mL. This difference was statistically significant based on the analysis using the 
independent t-test (p-value <0.05). Therefore, the administration of anti-tuberculosis drugs with the addition of 
iron can increase the body's immune response, which is indicated by the increasing level of IFN-γ.
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Pengaruh Penambahan Zat Besi Pada Pengobatan Obat Anti Tuberkulosis 
Terhadap Kadar Interferon-γ Pada Pasien Spondilitis Tuberkulosis
Abstrak
Tuberkulosis (TB) masih merupakan salah satu masalah kesehatan yang cukup besar di masyarakat. Gangguan 
imunitas tubuh penderita berperan dalam proses terjadinya infeksi tuberculosis. Mikronutrient yang penting 
dalam pertahanan tubuh salah satunya adalah zat besi. Pada penelitian ini akan dipelajari mengenai pengaruh 
penambahan zat besi pada terapi OAT terhadap kadar IFN-γ pada pasien spondilitis tuberkulosis. Penelitian ini 
merupakan penelitian dengan metode single blind randomized control trial di Rumah Sakit Dr. Hasan Sadikin 
Bandung pada Desember 2018 hingga Maret 2019 dengan metode pengambilan sampel consecutive sampling. 
Dilakukan randomisasi pada 34 responden. Responden yaitu: penderita spondilitis TB kategori 1 dengan kadar 
sTfR >21,7 pg/µL. Kelompok kontrol 17 responden diterapi 2 RHZE. Kelompok eksperimen 17 responden diterapi 
2 RHZE dengan tablet besi selama 2 bulan. Pada penelitian ini didapatkan peningkatan kadar IFN-γ rata-rata 
kelompok eksperimen (pemberian obat anti tuberkulosis dengan penambahan zat besi) dari 21,7 pg/mL sebelum 
dilakukan pemberian terapi menjadi rata-rata 72,39 pg/mL setelah dilakukan pemberian terapi diuji dengan uji t 
sampel independen (nilai p<0,05), secara statistik berbeda signifikan dengan kelompok kontrol (pemberian obat 
anti tuberkulosis), yaitu dari 22,5 pg/mL sebelum dilakukan pemberian terapi menjadi rata-rata 35,35 pg/mL 
setelah dilakukan pemberian terapi.  Simpulan, pemberian obat anti tuberkulosis dengan penambahan zat besi 
dapat meningkatkan respon imun tubuh, yang ditandai dengan meningkatnya kadar IFN-γ.
Kata kunci: Interferon-γ, spondilitis TB, zat besi
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Introduction
Spondylitis TB affects approximately 1–5% of 
the total TB patients.1,2 There are about 3 million 
deaths that occur each year due to this disease, 
making this disease one of the biggest health 
problems often found in society, especially in 
Indonesia.3 
Recovery from tuberculosis is declared 
based on various factors, one of which is the 
Interferon-γ (IFN-γ) level. An increase in the 
IFN-γ level reflects an increase in the patient’s 
immune response. Thus, the IFN-γ level can be 
used as a biomarker for tuberculosis recovery 
based on the measurement of the amount of 
IFN-γ in the blood.
Patients’ body immunity plays a role in the 
process of tuberculosis infection. One of the 
crucial micronutrients in the body’s defense is 
iron, which is an essential element of living beings 
and plays a decisive role in the body’s defense 
mechanism against pathogenic microorganisms. 
Iron deficiency can occur to anyone even if there 
is no symptom of anemia.4 This iron deficiency 
can be detected through the soluble transferrin 
receptor (sTfR) level since the increase level of 
sTfR is the sensitive response to the initial stages 
of iron deficiency.
No study has been conducted in Indonesian 
on the effect of the addition of iron to anti-TB 
drug therapy in patients. This study aimed to 
explore the effect of iron supplementation in anti-
TB drug therapy on the IFN-γ level in spondylitis 
tuberculosis patients.
Methods
A single-blind randomized control trial study 
was conducted in Dr. Hasan Sadikin General 
Hospital, Bandung, Indonesia from December 
2018 to March 2019. Respondents were 
randomly recruited using a consecutive approach 
based on the inclusion criteria, resulting in 34 
respondents being recruited. This study was 
approved by Dr. Hasan Sadikin General Hospital 
ethics committee in August 2018 (LB.04.01/
A05/EC/257/VIII/2018).
The population of this study was outpatient 
spondylitis TB patients aged 19–15 years old 
with an sTfR level of >21.7 mg/L treated at the 
Spine outpatient clinic of the Orthopaedics and 
Traumatology Department, Dr. Hasan Sadikin 
Bandung General Hospital (RSHS) and had never 
received anti-tuberculosis drug therapy.
Patients were divided into two groups of 17 
people each. The first group was the control 
group. In this group, patients were treated 
with anti-tuberculosis drugs (2RHZE) without 
iron supplementation. The second group was 
the experimental group in which patients 
were treated with anti-tuberculosis drugs 
(2RHZE) supplemented with iron (357mg iron 
polymaltose (III)).
All patients went through anamnesis, and 
clinical examinations were carried out by 
checking the vital signs and performing physical 
examination to obtain the history of the disease 
and clinical diagnosis. Furthermore, venous blood 
were drawn for examination of Hemoglobin level, 
LED, sTfR level, and Interferon-γ level. These 
examinations were performed before therapy 
and after the intensive phase of therapy, which 
was two months after the therapy was started.
Data were then analyzed statistically after the 
research objectives and hypothesis. Significance 
tests used to compare the characteristics of the 
two study groups were the independent t-test 
for data with normal distribution and the Mann-
Whitney test for data that were not normally 
distributed. Data obtained were recorded in a 
specific form and then processed using the SPSS 
version 25.0 for Windows.
Results
Table 1 explains the significance of pre-therapy 
between the control group and the experiment 
group. In age, sTfR, LED, and Hb variables, the 
significance level (α) of 0.05 was used. Results of 
the analysis on age, sTfR, LED, and Hb variables 
presented a p value of >0.05, meaning that all 
pre-therapy variables the control group were 
equivalent (i.e. different but not significant) 
with the experimental group. In the sex variable, 
the significance level of (α)=0.05 was used, 
resulting in a value of p>0.05, meaning that the 
pre-therapy variable for sex was equivalent 
(different but not significant) between the 
control group and experimental group. In the 
IFN-γ variable, the significance level of (α)=0.05 
was used. The IFN-γ variable presented a value 
of p>0.05, meaning the variable before therapy 
in the control group was equivalent (different 
but not significant) with the experimental group.
Table 2 explains the significance of post-
therapy between the control group and the 
experiment group. In the sTfR, IFN-γ, LED, and 
Hb variables, the significance level of (α)=0.05 
was used. The sTfR and IFN-γ variables had p 
values of <0.05, meaning that the variables of 
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Table 1 Pre-treatment Significance Test Results 
Variable Control Experiment p
Age (year)




Male 9 8 0.732
^Female 8 9
sTfr pre












Average 10.55 10.09 0.544
#SD 1.68 2.59
Median 10.60 9.40
^Chi Square test ; # independent t test; ! Mann-Whitney test
Figure 1  Comparison of IFN-γ Levels in the Group Given Anti-TB Drugs without Iron Supplementation 
    and the Group Given Anti-TB Drugs with Iron Supplementation
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Table 2 Post-treatment Significance Test
Variable Control Experiment p
sTfr post












Average 11.14 11.84 0.262
#SD 1.66 1.88
Median 11.7 11.6
#: independent t test
Figure 2 Comparison of sTfR Levels in the Group Given Anti-TB Drugs without Iron Supplementation 
and the Group Given Anti-TB Drugs with Iron Supplementation
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sTfR and IFN-γ after therapy in the control group 
differed significantly from the experimental 
group. The LED and Hb variables presented a 
value of p>0.05, meaning that the variables LED 
and Hb after therapy in the control group were 
equivalent (different but not significant) to the 
experimental group.
Discussion
Iron is a micronutrient needed by the body. Iron 
is essential for the activity of enzymes involved 
in crucial cellular functions, starting from 
respiration to DNA replication.5,6 Iron deficiency 
decreases the ability of neutrophils to kill 
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bacteria, decreases lymphocyte response, and 
interferes with Natural Killer (NK) cell activities.7 
In this study, supplementation of iron in anti-
TB drugs therapy and its effects on treatment 
response was assessed through a decrease in 
sTfR level in tuberculosis spondylitis patients 
before and after therapy. There were differences 
in the results of the sTfR levels before and after 
the supplementation of iron in anti-TB drug 
therapy that is due to increased iron deposits of 
enterocytes from the iron supplementation and 
reduced receptors in plasma membranes.
Gamma interferon (IFN-γ) is the main 
activator of macrophages that can increase the 
ability of macrophages to kill microorganisms 
by cytolytic mechanisms. IFN-γ is the cytokine 
that has the best potential for fighting against 
intracellular bacterial infections. Studies on the 
activation of antibacterial effector functions 
shows that IFN-γ plays an important role. The 
loss of IFN-γ can indicate an exacerbation of 
infectious diseases such as tuberculosis.8 IFN-γ 
plays a crucial role in the protection of MTB but 
also influences the cellular iron status. Activation 
of IFN-γ in monocytes regulates transferrin 
receptor (TfR) on the cell surface and the amount 
of iron macrophage gained from holo-transferrin 
are important in this mechanism. A decrease in 
IFN-γ levels indicates a microbacterial infection. 
The monocyte-derived macrophages feed on 
intracellular bacteria, such as Mycobacterium, 
which results in the secretion of interleukin-12 
(IL-12). IL-12 binds to its receptors on 
T-lymphocytes and NK cells, where it can trigger 
secretions from IFN-γ. IFN-γ will then be bound to 
the heterodimeric receptors on the macrophages 
and activate the microbial destruction function 
through the transducer’s signal mechanism.6,8 
IFN-γ is the main activator of macrophages 
to increase the ability of macrophages to kill 
microorganisms by cytolytic mechanisms. This 
effect of IFN-γ is gained through increased the 
production of reactive oxygen intermediates, 
including hydrogen peroxide, nitric peroxide, and 
indoleamine dioxygenase. IFN-γ strengthens the 
cytolytic activity of Natural Killer (NK) cells and 
also activates endothelial cells and neutrophil 
cells.8 Increased levels of IFN-γ can be used as a 
healing marker in tuberculosis patients.9 In this 
study, an increase in IFN-γ levels was seen from 
an average of 21.7 pg/mL to an average of 72.39 
pg/mL after the therapy in the IFN-γ treatment 
group receiving anti-tuberculosis drugs with 
iron supplement. This is in line with findings 
from various studies in pulmonary tuberculosis 
patients, showing an increase in the IFN-γ level 
after iron supplementation.
This study also used ESR as a measuring tool 
to assess the inflammatory process in spinal 
tuberculosis infections. Although ESR is a non-
specific marker in the inflammatory process, this 
examination is a simple examination that can be 
performed by peripheral laboratories and is a 
parameter for assessing therapeutic response 
and prognosis.10 Changes in ESR were seen, 
albeit statistically insignificant.
 Findings in this study correlate with those 
of previous studies on patients with pulmonary 
tuberculosis, in which the study suggested that 
administration of iron in pulmonary tuberculosis 
accelerates healing, which is characterized by 
increased IFN-γ. In a study conducted by Djoko 
Trihadi in 2009 that involved 252 respondents 
with pulmonary tuberculosis with iron-
deficiency anemia without  chronic disease and 
good nutritional status, it was demonstrated that 
iron supplementation increases the conversion 
of sputum smear in the experimental group by + 
100%, increasing the IFN-γ in the experimental 
group by + 324.84%.11 It this study, it was also 
evident that the addition of iron into the anti-
tuberculosis drug therapy in tuberculosis 
spondylitis patients increased the IFN-γ level in 
the experiment group by +333,59%.11
It is concluded that the administration of 
anti-tuberculosis drugs with the addition of 
iron can increase the body’s immune response 
as indicated by increasing levels of IFN-γ. 
The limitation of this study is the difficulties 
in achieving uniformity in regulating activity 
and food consumption to increase iron, and 
patient compliance to take iron every day. These 
limitations can be overcome in subsequent 
studies by involving patients with tuberculous 
spondylitis admitted to hospitals so patients’ 
activity pattern, dietary pattern, and regularity 
in iron consumption can be controlled. 
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